5
Poondra, R. R.; Iqbal, J.; Pal, M. Org. Biomol. Chem., 2011, 9,
3808; (e) Prasad, B.; Adepu, R.; Sandra, S.; Rambabu, D.;
Krishna, G. R.; Reddy, C. M.; Deora, G. S.; Misra, P.; M. Pal,
± 3.70%) of CM when tested at 50 µM. This was supported by
the initial docking of 3c into the CM that showed H-bond
between –CONH2 group of 3c with ILE 67 and TYR 110 residue
of CM. While detailed pharmacological studies of this class of
compounds are currently ongoing the compound 3c appeared to
be of further interest in view of the fact that tuberculosis is a
leading cause of death worldwide.
Chem. Commun., 2012, 48, 10434; (f) Oskooie, H. A.; Heravi, M.
M.; Behbahani, F. K. Molecules 2007, 12, 1438.
4.
(a) Hiroya, K.; Itoh, S.; Sakamoto, T. Tetrahedron, 2005, 61,
10958; (b) Hiroya, K.; Itoh, S.; Sakamoto, T. J. Org. Chem., 2004,
69, 1126; (c) Cacchi, S.; Fabrizi, G.; Parisi, L. M. Org. Lett., 2003,
5, 3843; (d) Hiroya, K.; Itoh, S.; Ozawa, M.; Kanamori, Y.;
Sakamoto, T. Tetrahedron Lett., 2002, 43, 1277; (e) Ezquerra, J.;
Pedregal, C.; Lamas, C.; Barluenga, J.; P´erez, M.; Garc´ıa-
Mart´ın, M. A.; Gonz´alez, J. M. J. Org. Chem., 1996, 61, 5804;
(f) Ambrogio, I.; Arcadi, A.; Cacchi, S.; Fabrizi, G.; Marinelli, F.
Synlett, 2007, 1775; (g) Zhang, Y.; Donahue, J. P.; Li, C. J. Org.
Lett., 2007, 9, 627; (h) Li, X.; Chianese, A. R.; Vogel, T.;
Crabtree, R. H. Org. Lett., 2005, 7, 5437; (i) Kurisaki, T.; Naniwa,
T.; Yamamoto, H.; Imagawa, H.; Nishizawa, M. Tetrahedron
Lett., 2007, 48, 1871; (j) McDonald, F. E.; Chatterjee, A. K.
Tetrahedron Lett., 1997, 38, 7687; (k) Shimada, T.; Nakamura, I.;
Yamamoto, Y. J. Am. Chem. Soc., 2004, 126, 10546; (l) Trost, B.
M.; McClory, A. Angew. Chem., Int. Ed., 2007, 46, 2074.
For selected reviews, see: (a) Cacchi, S.; Fabrizi, G. Chem. Rev.,
2005, 105, 2873; (b) Leni, G.; Larock, R. C. Chem. Rev., 2004,
104, 2285; (c) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem.
Rev., 2003, 103, 893; (d) Knolker, H.-J.; Reddy, K. R. Chem. Rev.,
2002, 102, 4303.
NH2
NH2
O
O
Me
Cu
Me
Cu
N
N
R1
N
N
R1
N
N
N
N
SO2R3
R2
SO2R3
R2
Fig. 5. Resonance stabilization of E-6 generated from 3.
In conclusion, we have described the rare use of
propargylamine (secondary) as a building block in the synthesis
of 2-substituted indoles. Accordingly, ultrasound assisted
methodology has been developed to prepare (i) indoles via
Pd/Cu-catalyzed coupling-cyclization strategy and (ii) certain
imines via Cu-catalyzed aerobic oxidation of precursor amines.
Initially indoles containing a pyrazole moiety at C-2 attached via
the -CH2NH- linker were synthesized that were originally
designed as potential anti-tubercular agents. Thus 1-methyl-4-
(prop-2-ynylamino)-3-propyl-1H-pyrazole-5-carboxamide was
coupled for the first time with a variety of 2-iodoanilides to
afford novel indoles in 70-82% yield. Subsequently, the scope
and generality of this methodology was expanded by preparing
similar but simpler indole derivatives in 75-83% yield. The
unexpected formation of imine side products in certain cases
helped in synthesizing related (pyrazole)imines in 65-78% yield.
While this finding seemed to be uncommon the results however
indicated that the imine formation was favored by the presence of
N-methylpyrazole moiety. The initial chorismate mutase
inhibitory properties of these indole derivatives highlighted their
potential for further Med Chem effort. Overall, the current
research related to propargylamine / indole chemistry could
attract further interest.
5.
6.
Liu, Y.; Huang, Y.; Song, H.; Liu, Y.; Wang, Q. Chem. - Eur. J.
2015, 21, 5337.
7.
8.
Xia, G. Q.; Han, X. L.; Lu, X. Y. Org. Lett. 2014, 16, 2058.
Zhang, X.; Campo, M. A.; Yao, T.; Larock, R. C. Org. Lett. 2005,
7, 763 - 766
9.
Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y. N.;
Al-aizari, F. A.; Ansar, M. Molecules 2018, 23, 134;
doi:10.3390/molecules23010134
10. (a) Due to its absence in animals but not in bacterial
Mycobacterium tuberculosis H37Rv chorismate mutase (CM) is
considered as a promising target for the identification of new and
potential antitubercular agents, for a review, see: Khanapur, M.;
Alvala, M.; Prabhakar, M.; Kumar, K. S.; Edwin, R. K.; Saranya,
P. S. V. K. S.; Patel, R. K.; Bulusu, G.; Misra, P.; Pal, M. Bioorg.
Med. Chem. 2017, 25, 1725; (b) see also: End to killer TB?
Scientists identify an enzyme that may hold clue;
R. M.; Sandra, S.; Kapavarapu, R.; Rambabu, D.; Krishna, G. R.;
Reddy, C. M.; Ravada, K.; Misra, P.; Iqbal, J.; Pal, M. Med.
Chem. Commun. 2011, 2, 1006; (d) The discovery and
development of novel chemical class of molecules / agents is
considered as one of the powerful approaches to overcome
existing resistance mechanisms and combat life-threatening
infections caused by bacteria.
Acknowledgements
GSR thanks DST, India for
a INSPIRE fellowship
11. Indeed, the pyrazolecarboxamide derivatives have been explored
as potential antifungal agents, see: Mu, J.-X.; Shi, Y.-X.; Yang,
M.-Y.; Sun, Z.-H.; Liu, X.-H.; Li, B.-J.; Sun, N.-B. Molecules
2016, 21, 68.
(IF160590). Authors thank the Management of DRILS,
Hyderabad, India and Manipal University, Manipal, India for
encouragement and support and DBT, New Delhi, India for
financial assistance (Grant No. BT/PR12817/COE/34/23/2015).
Authors also thank Prof P. Misra and Ms. R. Edwin of DRILS,
Hyderabad for in vitro assay.
12. The propargyl amine 1a was prepared in 80% yield via the
reaction of 4-amino-1-methyl-3-propyl-1H-pyrazole-5-
carboxamide with propargyl bromide in the presence of K2CO3 in
DMF at room temp for 5h.
13. (a) Ohno, H.; Ohta, Y.; Oishi, S.; Fujii, N. Angew. Chem., Int. Ed.,
2007, 46, 2295; (b) Ohta, Y.; Chiba, H.; Oishi, S.; Fujii, N.; H.
Ohno, J. Org. Chem., 2009, 74, 7052.
Supplementary data
14. For a review on antimicrobial activities of Schiff bases, see: da
Silva, C. M.; da Silva, D. L.; Modolo, L. V.; Alves, R. B.; de
Resende, M. A.; Martins, C. V. B.; Fátima, Â. J. Adv. Res. 2011,
2, 1-8
Supplementary data associated with this article can be found,
in the on line version, at xxxxxxxxx
15. (a) Crystal Data for 3a: C19H25N5O3S (M =403.50 g/mol):
monoclinic, space group P21/c (no. 14), a = 12.012(2) Å, b =
12.463(2) Å, c = 14.490(3) Å, β = 109.11(3)°, V = 2049.6(7) Å3,
Z = 4, T = 294.15 K, μ(MoKα) = 0.188 mm-1, Dcalc =
1.308 g/cm3, 56864 reflections measured (4.42° ≤ 2Θ ≤ 55.348°),
4772 unique (Rint = 0.0232, Rsigma = 0.0126) which were used in
all calculations. The final R1 was 0.0497 (I > 2σ(I)) and wR2 was
0.1515 (all data). CCDC 1867683 contains supplementary
Crystallographic data for the structure. (b) Crystal Data for 4b:
C25H26N5O3SCl3 (M =582.92 g/mol): monoclinic, space group
P21/n (no. 14), a = 14.0837(3) Å, b = 8.9510(2) Å, c =
21.8716(4) Å, β = 101.1726(6)°, V = 2704.95(10) Å3, Z = 4, T =
294.15 K, μ(MoKα) = 0.453 mm-1, Dcalc = 1.431 g/cm3, 46657
reflections measured (4.93° ≤ 2Θ ≤ 56.828°), 6746 unique (Rint =
0.0578, Rsigma = 0.0410) which were used in all calculations. The
final R1 was 0.0505 (I > 2σ(I)) and wR2 was 0.1290 (all data).
CCDC 1867705 contains supplementary Crystallographic data for
the structure.
References and notes
1.
2.
For an in depth review, see: Lauder, K.; Toscani, A.; Scalacci, N.;
Castagnolo, D. Chem. Rev., 2017, 117, 14091.
(a) Cacchi, S.; Fabrizi, G.; Parisi, L. M. Org. Lett., 2003, 5, 3843;
(b) Cacchi, S.; Fabrizi, G.; Parisi, L. M.; Bernini, R. Synlett, 2004,
287; (c) Slough, G. A.; Krchnak, V.; Helquist, P.; Canham, S. M.
Org. Lett., 2004, 6, 2909; (d) Liu, F.; Ma, D. J. Org. Chem., 2007,
72, 4844.
3.
(a) Pal, M.; Subramanian, V.; Batchu, V. R.; Dager, I. Synlett,
2004, 1965; (b) Layek, M.; Lakshmi, U.; Kalita, D.; Barange, D.
K.; Islam, A.; Mukkanti, K.; Pal, M. Beilstein J. Org. Chem.,
2009, 5, DOI: 10.3762/bjoc.5.46; (c) Nakhi, A.; Prasad, B.;
Reddy, U.; Rao, R. M.; Sandra, S.; Kapavarapu, R.; Rambabu, D.;
Krishna, G. R.; Reddy, C. M.; Ravada, K.; Misra, P.; Iqbal, J.; Pal,
M. Med. Chem. Commun., 2011, 2, 1006; (d) Rao, R. M.; Reddy,
U.; Nakhi, A.; Mulakayala, N.; Alvala, M.; Arunasree, M. K.;